Home

 Accelerate Your Clinical Research Projects Clinical Trial Evaluation Approval Performances
Share

Approval Performances

Filters (0)
Apply filters

1-12 of 87 results

Clear filters
21466 (Fiore)
Cardiology Phase III
  • 8 weeks
  • 1st site activated worldwide
BANTAM-01
Hepatocellular Carcinoma Phase I
  • 13 weeks
  • 1st site activated worldwide
BANTAM-01
Hepatocellular Carcinoma Phase I
  • 12.8 weeks
  • 1st site activated worldwide and FPI globally
BANTAM-01
Hepatocellular Carcinoma Phase I
  • 15.2 weeks
  • 2nd site activated worldwide
Read the news
BO45853 (NeoTOV)
Breast Cancer Phase II
  • 10.8 weeks
  • 2nd site activated worldwide and FPI globally
BO45853 (NeoTOV)
Breast Cancer Phase II
  • 9 weeks
  • 1st site activated worldwide
BO45853 (NeoTOV)
Breast Cancer Phase II
  • 8.6 weeks
  • 3rd site activated worldwide
ARTEMIDE-Lung03
Lung Cancer Phase III
  • 8 weeks
  • 2nd site activated worldwide and FPI globally
Read the news
PAnTHA-PSMA Trillium
Prostate Cancer Phase I
  • 10.4 weeks
  • 1st site activated worldwide and FPI globally
PAnTHA-PSMA Trillium
Prostate Cancer Phase I
  • 5.4 weeks
PAnTHA-PSMA Trillium
Prostate Cancer Phase I
  • 19.2 weeks
Read the news
PSMA-DC
Prostate Cancer Phase III
  • 9.4 weeks
  • 1st site activated in Canada and FPI globally 
PSMA-DC
Prostate Cancer Phase III
  • 8.8 weeks
  • 2nd site activated in Canada
Read the news
PSMACare
Prostate Cancer Phase II
  • 9 weeks
  • 1st site activated in Canada and FPI globally
PSMACare
Prostate Cancer Phase II
  • 8.8 weeks
  • 2nd site activated in Canada
CO44657 (pionERA)
Breast Cancer Phase III
  • 10.2 weeks
  • 3rd site activated in Canada - 4th site activated worldwide - 1st and 2nd patient enrolled globally
CO44657 (pionERA)
Breast Cancer Phase III
  • 8.8 weeks
CO44657 (pionERA)
Breast Cancer Phase III
  • 9 weeks
  • 4th site activated in Canada - 5th site activated worldwide and 3rd patient enrolled worldwide
CO44657 (pionERA)
Breast Cancer Phase III
  • 12.6 weeks
CO44657 (pionERA)
Breast Cancer Phase III
  • 15.6 weeks
Read the news
Galaxies 202
Head and Neck Cancer Phase II
  • 8.8 weeks
  • 1st site activated worldwide
Read the news
SIRIUS-SLE1
Lupus Phase III
  • 7 weeks
  • 1st site activated worldwide and second patient enrolled globally
1501-001
Advanced Solid Tumours Phase I
  •  7.1 weeks
  • 1st site activated worldwide and Canadian FPI
Read the news
ProHer
Breast Cancer Phase IIIb
  • 10.6 weeks
  • 1st site activated worldwide
ProHer
Breast Cancer Phase IIIb
  • 25 weeks
Read the news

Use the FAST TRACK Evaluation Service to Start Your Clinical Trials

Learn more Contact us